




Background. Oxidative stress (OS) is the main triggering factor for the onset and developing of most degenerative diseases hard to
fight with existing synthetic drugs without adverse side effects. Gallic acid (GA) 1, is a natural triphenolic acid present in several plants,
fruits and common foodstuffs (Fig.1). It is provided both with the basic nutritional values and with several extra health benefits such as a
remarkable antioxidant power and it has exhibited abilities in protecting cells from OS via a number of pathways without triggering
unpleasant side effects.1 Unfortunately, GA clinical application is limited by its pharmacokinetic drawbacks, poor bioavailability, slow
GIT absorption, fast metabolism and short half-life. Dendrimer nanoparticles, thanks to their nonpareil physicochemical properties, are
extensively exploited in nanomedicine to control molecular weight, hydrophilicity, solubility,2-4 bioavailability and pharmacokinetic
behaviour of drugs as well as to protect them from early degradation or fast metabolism. Among dendrimers, PAMAMs are very efficient
and continuously under study, but because of their non-biodegradability and excessive cationic charge, they may cause irreparable
damage to cells and require laborious modifications to be in vivo used. Therefore, nowadays, uncharged polyester-based hydrolysable
dendrimer scaffolds are preferred.
Present Work. With the aim at minimizing GA limitations for allowing its clinical applications, in this study, the G5 polyester-based
dendrimer 2 with 64 peripheral OH functions exploitable for further esterification, was prepared and subsequently, it was decorated


















Chemistry. Dendrimer 2 was
synthetized by esterification
of the 1, 2-propandiol,
selected as dendrimer
“core”, with the fifth
generation dendron D5A (Fig.
2)5 to achieve the acetonide
protected dendrimer G5A.
Subsequently, it was exposed
to acidic conditions by
treatment with Dowex resins
H+ to give 2 (Scheme 2).


































Dendrimer 2 was esterified with the acid chloride derivative of 1 protected to the
phenols groups6 to avoid side reactions and/or uncontrolled polymerisation.The
subsequent protecting groups removal, by the treatment with acethyl chloride and
alcohols, provided the final GA-enriched dendrimer 3 (Scheme 2). Once the presence
of free OH groups was proved by performing the FeCl3 essay (Fig. 2), the structure of
3 was confirmed by FTIR, NMR and Elemental analysis. Then, 3 was investigated to
determine its potentials as innovative antioxidant device to be used as safer





Fig. 1 Gallic acid 1
Antioxidant activity and biodegradability investigations. Firstly, the intrinsic
antioxidant power of 3 was determined by performing the DPPH test obtaining its
Radical Scavenging Activity (RSA%). In parallel, for comparison, GA, Vitamin A, E and
Trolox were also essayed. The results were reported as IC50 and are shown in Graph
1. Secondly, an in vitro reproduction of what could happen to 3 because of an
enzymatic attack by cells esterase, was conceived and realized, for ascertaining the
actual behaviour and fate of 3 once inside the cell. So, 3 was treated at 37 °C, for 24
hours, in PBS with the commercial Pig Liver Esterase (PLE). After the recover of the
crude solid product, investigation by FeCl3 assay, TLC analysis, recrystallization, m.p.
and NMR, showed that the main detectable component was the bioactive GA.
Results. Dendrimer 3 showed an antioxidant power four time higher than free GA and
proved to be able to degrade by cell esterase hydrolytic action to non cytotoxic small
molecules setting free the bioactive GA units for additional antioxidant effects, as






Fig. 2. FeCl3 Test: characteristic
green colouring of  high molecular 
weight GA-esters.
CONCLUSIONS. By merging synthetic processes and the healthy chemistry of
natural compounds, this study led to get a GA-enriched biodegradable, non cytotoxic
antioxidant dendrimer (3) more powerful than free GA and than other known
antioxidants. Compound 3 also embodies the features of a GA delivering device, able
to carry several bioactive GA units at once, thus improving its pharmacokinetic and
preserving it from fast metabolism. In physiological condition, i.e. as inside the cell, 3
degrades to non cytotoxic molecules and releases bioactive GA units by esterase
action. The achieved GA-prodrug can be considered an innovative double-acting
therapeutic with high potentials for the treatment of diseases triggered by OS.
Graph 1. IC50 mM of 3, GA, Vit. A, Trolox and Vit. E 




By connecting a synthetic scaffold and a natural shell of  gallic acid: an innovative 
double-acting antioxidant device to fight «oxidative stress»











































































Scheme 1. Key  structures achieved: the polyester-based dendrimer 
matrix 2 and the final GA-enriched dendrimer3
Scheme 2 
Studies currently in progress, are proving that dendrimer 3 works
very well and much more better than the free GA as a preservative
additive against the oxidative degradation of essential oils, as an
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..even
for us..
It’s The End!!!
